myasthenia gravis
Market Access/ News/ News/ News/ Patients
UK grants early access to Argenx’ efgartigimod for myasthenia gravis
Phil Taylor
access, Argenx, efgartigimod, MHRA, myasthenia gravis, patients, rare disease, UK, Vyvgart
0 Comment
With rivals threatening, Argenx scores key myasthenia gravis win
Phil Taylor
Argenx, efgartigimod, myasthenia gravis, Vyvgart
0 Comment
UCB preps filings for another challenger to AZ’s Soliris
Phil Taylor
Apellis Pharma, Argenx, AstraZeneca, myasthenia gravis, rozanolixizumab, Soliris, UCB, Ultomiris, zilucoplan
0 Comment
UCB chases after Argenx with FcRN drug for myasthenia gravis
Phil Taylor
Argenx, autoimmune disease, efgartigimod, myasthenia gravis, rozanolixizumab, UCB
0 Comment
Myasthenia Gravis approval will boost Soliris revenues
Andrew McConaghie
Alexion, myasthenia gravis, Rare diseases, Soliris
0 Comment